ad image

End-to-End

1 / 2
Navigating mRNA Manufacturing with Flexibility and Innovation
mRNA Manufacturing

Navigating mRNA Manufacturing with Flexibility and Innovation

Michael van der Horst, Ph.D.

PAO-04-24-CL-02Apr 08, 2024
The Innovators Bringing Continuous Manufacturing to Lipid Nanoparticles
mRNA–LNP Manufacturing

The Innovators Bringing Continuous Manufacturing to Lipid Nanoparticles

Antonio Costa, Ph.D.; William Pasek

DIANT Pharma

PAO-03-24-CL-08Mar 18, 2024
Maximizing Outsourcing Benefits for Virtual Pharma Companies
CDMO

Maximizing Outsourcing Benefits for Virtual Pharma Companies

William Kazimier

Tedor Pharma Services

PAO-09-23-CL-08Jan 11, 2024
Facilitating Development and Scale-Up of Nanoparticle Drug Products with an End-to-End Adaptable Manufacturing Platform
Lipid Nanoparticles

Facilitating Development and Scale-Up of Nanoparticle Drug Products with an End-to-End Adaptable Manufacturing Platform

Antonio Costa, Ph.D.

DIANT Pharma

PAO-10-23-CL-03Nov 01, 2023
Webinar: A Developer's Guide to Partnering With the Right CDMO, Presented by Samsung Biologics
CDMO Partnerships

Webinar: A Developer's Guide to Partnering With the Right CDMO, Presented by Samsung Biologics

Samsung Biologics

PAO-08-23-PATV-01Aug 16, 2023
Reach the Patient Quicker with GBI’s Manufacturing Solutions
Clinical and Commercial Manufacturing

Reach the Patient Quicker with GBI’s Manufacturing Solutions

Muctarr Sesay, Ph.D.

GBI

PAO-08-23-CL-02Aug 08, 2023
Building on Experience and Investing in an Integrated mRNA Offering
New Integrated mRNA Offering

Building on Experience and Investing in an Integrated mRNA Offering

Jessica Madigan; Normand Blais

BIOVECTRA

PAO-07-23-CL-03Jul 31, 2023
On the Journey to Support Drug Developers With End-to-End Outsourcing
Expanded CDMO Capabilities

On the Journey to Support Drug Developers With End-to-End Outsourcing

Michelle Hall

Mikart

PAO-06-23-CL-04Jul 17, 2023
Why Choosing the Right CDMO Partner is Essential in Today’s Pharmaceutical Market
CDMO Partnerships

Why Choosing the Right CDMO Partner is Essential in Today’s Pharmaceutical Market

Daniel Buckley

Samsung Biologics

PAO-05-23-CL-07Jun 19, 2023
Facilitating Lipid Nanoparticle Production with a Unique Continuous Manufacturing Solution
Lipid Nanoparticles

Facilitating Lipid Nanoparticle Production with a Unique Continuous Manufacturing Solution

Antonio Costa, Ph.D.; William Pasek

DIANT Pharma

PAO-04-23-CL-05May 06, 2023
Unleashing the Power of the Microbiome: Advancements, Challenges, and the Therapeutic Future
Microbiome Therapeutic Innovation

Unleashing the Power of the Microbiome: Advancements, Challenges, and the Therapeutic Future

Stacy Burns-Guydish, Ph.D.; Gary Henderson

List Labs

PAO-03-23-CL-08Apr 04, 2023
Considerations in Viral Vector Analytical Development to Enable Smooth Transfer to Quality Control
Viral Vector Manufacturing

Considerations in Viral Vector Analytical Development to Enable Smooth Transfer to Quality Control

Chris Berger; Kilian Witzel

Avid Bioservices

PAO-02-23-CL-03Mar 14, 2023
Ultra-Cold Chain and Supply Chain Management Strategies for mRNA
mRNA Ultra-Cold Chain Management

Ultra-Cold Chain and Supply Chain Management Strategies for mRNA

Eunseo (Ency) Lee, Ph.D; Jungkeun (Henry) Oh; Hanel Hwang

Samsung Biologics

PAO-02-23-CL-09Mar 09, 2023
Staying Ahead of the Curve with Outsourced Program Management
Pharmaceutical Consultancy

Staying Ahead of the Curve with Outsourced Program Management

PharmaLex

PAO-02-23-PATV-01Feb 07, 2023
Controlled Substances in Clinical Trials: Considerations, Challenges, and Growing Demand
Controlled Substances in Clinical Trials

Controlled Substances in Clinical Trials: Considerations, Challenges, and Growing Demand

Rich Nelson; John Hufnagel; Rachel Castro

PCI Pharma Services

PAO-01-23-CL-03Jan 30, 2023
Overcoming the Challenges of an Ever-changing Biopharma Landscape

Overcoming the Challenges of an Ever-changing Biopharma Landscape

Integrity

PAO-01-23-PATV-01Jan 24, 2023
A Concerted QbD Approach to Development and Manufacturing of Nucleic Acid Therapies
Quality by Design

A Concerted QbD Approach to Development and Manufacturing of Nucleic Acid Therapies

Lynda Menard, Ph.D.; Grant Henderson, Ph.D.

Vernal Biosciences

PAO-11-022-CL-06Jan 10, 2023
Expanding a Leadership Position in Microbiome-Based Contract Development and Manufacturing
Microbiome-Based CDMO

Expanding a Leadership Position in Microbiome-Based Contract Development and Manufacturing

Stacy Burns-Guydish, Ph.D.; Jonathan Yongwan Jo; Gary Henderson; Michael Kimble

List Labs

PAO-11-022-CL-13Dec 13, 2022
New Name, Same Expertise: Goodwin Biotechnology is Becoming GBI!
Biomanufacturing

New Name, Same Expertise: Goodwin Biotechnology is Becoming GBI!

Danielle Alvarez

Pharma's Almanac

PAO-11-022-CL-11Dec 05, 2022
Platform Processes and End-to-End Capabilities Position Vernal Biosciences as a Critical CDMO Resource for mRNA Developers
mRNA Manufacture

Platform Processes and End-to-End Capabilities Position Vernal Biosciences as a Critical CDMO Resource for mRNA Developers

Tonia Becker

Nice Insight

PAO-10-022-CL-03Oct 25, 2022
1 / 2